Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations

Effectively targeting leukemia-initiating cells (LIC) in FLT3-ITD-mutated acute myeloid leukemia (AML) is crucial for cure. Tyrosine kinase inhibitors (TKI) have limited impact as single agents, failing to eradicate LIC in the bone marrow. Using primary AML samples and a patient-derived xenograft mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Garz, Anne-Kathrin, Wolf, Saskia, Grath, Sonja, Gaidzik, Verena, Habringer, Stefan, Vick, Binje, Rudelius, Martina, Ziegenhain, Christoph, Herold, Sylvia, Weickert, Marie-Theresa, Smets, Martha, Peschel, Christian, Oostendorp, Robert A.J., Bultmann, Sebastian, Jeremias, Irmela, Thiede, Christian, Döhner, Konstanze, Keller, Ulrich, Götze, Katharina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752477/
https://www.ncbi.nlm.nih.gov/pubmed/29312564
http://dx.doi.org/10.18632/oncotarget.21877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752477/
https://www.ncbi.nlm.nih.gov/pubmed/29312564
http://dx.doi.org/10.18632/oncotarget.21877

Ejemplares similares